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transcription factor NF-kB is essential for the transcription of iNOS. The aim of this study 
was to assess wether NF-kB is activated in skeletal muscle of patients (pts) with CHF 
and linked to the expression of iNOS. 
Methods: Skeletal muscle biopsies were obtained from 7 CHF-pts (NYHA I1-~11; LVEF 19 
± 2%; VO2max 14.0 ± 1.3 ml/kg/min) and 7 healthy controls (HC) (LVEF 71 ± 2%; 
VO2max 28.3 ± 2.7 ml/kg/min). Nuclear proteins were isolated and the content of acti- 
vated NF-kB was analyzed by etectrophoretic mobility shift assay (EMSA). iNOS expres- 
sion in SM was determined by real time PCR and TNF-a concentration in the serum was 
measured by ELISA. 
Results: The expression of [NOS and the activation of NF-kB in the SM was significantly 
increased in CHF pts as compared to healthy controls (iNOS: 0.30 ± 0.04 vs. 0.09 ± 0.03 
relative RNA expression, p<0.01; NF-kB: 0.48 ± 0.10 vs. 0.12 ± 0.05 relative units). Addi- 
tionally serum TNF-a was significantly increased in CHF pts (CHF: 5.2 ± 0.6 vs. HC: 1.5 
± 0.2 pg/ml; p<O.001 ). Furthermore, a signifcant linear correlation was observed between 
NF-kB activation and iNOS expression (r--0.71, p<0.01) as well as between serum TNF- 
a and NF-kB activation ( r--O.8, p<0.01) 
Conclusion: The results of this study indicate for the first time that in skeletal muscle of 
patients with chronic heart failure the activation of transcription factor NF-kB is increased 
and may represent one important regulatory factor for the expression of )NOS. 
1156-143 Exposure  o f  Normal Adult Cediomyocytes to Active 
Caepaae-8 Triggers the Release of Cytochrome C From 
MItochondria Suppresses Mitochondrial Respiration 
Victor G. Sharov. Anastassia V. Tedor, Sidney Goldstein, Hani N. Sabbah, Henry Ford 
Health System, Detroit, Michigan. 
Background: We previously showed that mitochondrtal respiratory abnormalities exist in 
cardiomyocytes of human with end-stage heart failure as well as in cardiomyocytes of 
dogs with intracoronary microembolization-induced chronic heart failure. The factors that 
promote these abnormalities remain uncertain. One possible factor is activation of 
caspase-8 which, by activating Bid, promotes the release of cytochrome c from mlto- 
chondria that, in turn, results in mitochondrial dysfunction. In the present study, we tested 
the hypothesis that exposure of normal adult cardiomyocytes to active caspase-8, acti- 
vates bid, causes the release of cytochrome c from mitochondria nd adversely impacts 
mitochondrial respiration. 
Methods: Cardiomyocyte were enzimatically isolated from left ventdcular myocardium of 
5 normal dogs. Cardiomyocytes were saponin skinned, incubated under normoxic condi- 
tions (95%air/5%CO2), and exposed to active caspase-8 (100U/mr) for one hour. All- 
quotes of cardiomyocytes incubated with and without active caspase-8 were used to 
measure mitochondrial state 3 respiration with Clark electrode in the presence of 3 mM 
malate, 5 mM glutamate and 1 mM ADP. A second set of aliquotes of cardiomyocytes 
was centrifuged at 15,000 g and the supernatant used to measure the expression of 
cytosolic cytoohrome c and a third set was homogenized and the homogenate used to 
measure the expression of Bid by Western blotting. 
Results: Exposure of cardiomyocytes to active caspase-8 resulted in cleavage of Bid 
into 15 kDa fragments and markedly increased cytosolic cytochrome c (2.4 + 0.3 vs. 25.2 
_-t: 0.8, P<0.001) compared to unexposed cardiomyocytes. Exposure to caspase-8 also 
caused a significant decrease in mltochondrial state 3 respiration (39 -+ 4 vs. 64 -+ 13 ng 
atoms O2imin/mg protein, P<0.001 ). 
Conclusions: These results indicate that exposure of normal adult cardiomyocytes to 
active caspasa-8 triggers cleavage of Bid and the release of cytochrome c from mito- 
chondria with subsequent suppression of state respiration. This cascade of events offers 
an explanation for the observed abnormalities of mitochondrial respiration seen in heart 
failure. 
1156-144 Th io redox ln :  A New Marker of  Ox idat ive  St ress  in 
Patients With Chronic Heart Failure 
Andraas Jekell, Akter Hossain, Anders Rosdn, Ulf Dahlstrdm, LinkSping University, 
Link6ping, Sweden. 
Background: It is well known that pro-inflammatory cytokines are important prognostic 
markers in chronic heart failure (CHF) patients and it has been shown that tumor necro- 
sis factor-~x (TNFc¢) is elevated in plasma of CHF patients. Elevated levels of TNF~ are 
correlated with New York Heart Association (NYHA) functional class. Thioredoxin (Trx) is 
a multifunctional redox-protein, which regulate the intra- and extra cellular redox-environ- 
ment. One important function of Trx is the protection from oxidative stress caused by free 
radicals and pro-inflammatory cytokines. Trx is upregulatad both during chronic and 
acute oxidative conditions. However, it is not known whether Tr'x is elevated in systemic 
circulation in patients suffering from CHF. The aim of this study was to investigate possi- 
ble mechanisms behind CHF with special emphasis on the activation of cytokines and to 
see whether oxidative stress was playing a role. In order to assess these complex pro- 
cesses in CHF, we analyzed plasma levels of the redox-active proteins Trx and Trx- 
reductase (TrxR) as markers of oxidative stress and TNF(x and intedeukin 6 (IL6) as pro- 
inflammatory cytokines. 
Methoda: 27 male patients with CHF, NYHA class I1-111, and mean age 74 _+ 5 years 
(range 65-82) were compared to 30 healthy subjects of similar age-groups, mean age 75 
_+ 5 years (range 64 - 81). Plasma samples were collected in the morning after rest for 30 
min in supine position and analyzed in enzyme-linked immunosorbent assays (ELISA) for 
TNF, Trx, TrxR and IL6. 
Results: Patients with CHF showed a significant increase of Trx in plasma, mean 32 +__5 
(SEM) ng/ml, compared to healthy subjects (16 +4 ng/ml); p < 0.0001. Variations of 
plasma Trx were found in patients with CHF (range 9-101 ng/ml) as well as in healthy 
subjects (range 4-117 ng/ml). No significant differences in TNF~, IL6 nor TrxR concentra- 
tions were seen between the two groups. 
Conclusions: The most important finding in our pilot study is that Trx was significantly (p 
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< o.o0ol) elevated in patients with CHF compared to healthy subjects of similar age 
groups. This finding indicates that Trs may be a new sensitive marker of oxidative stress 
in CHF. 
1156-145 Anticytokine Therapy Alleviates Oxidative Stress and 
Attenuates Left Ventricular Remodeling in Experimental 
Heart  Fa i lure 
Gordon W. Moe, Andrea Konig, Marina Romanova, Peter Liu, St Michael's Hospital, 
Toronto, Ontario, Canada, University Health Network, Toronto. Ontario, Canada. 
Background: Increased expression of the prdmflammatory cytokine tumor necrosis fac- 
tor-alpha (TNF-(~) and increased oxidative stress have been observed in the failing head. 
TNF-c~ is known to induce oxidative stress /n vitro. Accordingly, this study tested the 
hypothesis that TNF-(x would also induce oxidative stress in vivo and contribute to LV 
dysfunction and remodeling in heart failure (HF). 
Methods: Dogs were randomly assigned to: (1) no pacing (controls, n=10), (2) chronic 
pacing for 4 weeks to severe HF (HF, n=10), and (3) pacing with concomitant reatment 
with etanercept, a chimeric TNF-~ soluble receptor, 0.5 mg/kg twice weekly SC (HF- 
etanercept, n=10). LV tissue level of aldehyde, an accurate marker of oxidative stess, 
was measured using gas chromatography/mass spectroscopy. LV function and remodel- 
ing was assessed by echocardlography. 
Results: LV tissue total aldehyde level increased markedly in HF, indicating severe oxi- 
dative stress. Selected unsaturated aldehydes such as 4-OH hexenal and malondialde- 
hyde were also increased. This was accompanied by reduced LV ejection fraction (LVEF) 
and increased LV volume (LVV), reflective of LV dysfunction and remodeling. Treatment 
with etanercept normalized LV aldehyde levels, reduced LVV, and partially restored 
LVEF. 
Conclusion: Our data provide supportive evidence that TNF.(x contributes to LV dys- 
function and remodeling in canine pacing-induced CHF, mediated in part by a local 
increase in oxidative stress. 
* p<O,OOl ve controls, ** p<O.O5 ve HF 
Controls HF HF-etanercept 
LVV (ml/kg) 3.4 + 0.5 5.2 + 0.4" 4.0 + 0.2** 
LVEF (%) 53 +_2 19 + 3* 26 + 2** 
Aldehydes (pmol/100 rag) 7048_+448 11760_+1410" 6991_+516"* 
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1157-153 A Simple Model to Predict Left Ventricular Systolic 
Dyefunction in a Multiethnic Community 
Gavin I. Gatasko, Roxy Senior, Avijit Lahid, Cardiology Research Department, Northwick 
Park Hospital, Harrow, United Kingdom. 
Background: Community-based programmes to screen for and treat left ventricular sys- 
tolic dysfunction (LVD) have recently been advocated. However, who best to invite for 
screening has not yet been fully elucidated. This study was undertaken to assess this fur- 
ther. 
Methods: 1403 subjects _> 45 years old were chosen at random from 7 geographical and 
socio-economically representative community practices to undergo a clinical assess- 
ment, symptom questionnaire, ECG, echocardiogram and fasting blood tests. A multi- 
variate model to predict the presence or absence of LVD was then constructed using 
both clinical and biochemical parameters. 
Results: 730 subjects (52%) attended. 515 (71%) were Caucasian and 168 (26%) South 
Asian. An ejection fraction (EF) was calculable by echocardiography using Simbson's 
apical biplane rule in 700 cases (96%). 38 subjects (5.4%) were found to have LVD. Of 
these 19 (50%) were entirely asymptomatic. Multivariate predictors of LVD included prior 
myocardial infarction, diabetes, a history of heavy alcohol usage, male sex, abnormal 
ECG and plasma N-terminal proBNP levels. No significant differences were seen with 
ethnicity. A multivariate model to predict LVD using these 6 parameters was constructed. 
It gave an area under the ROC curve of 0.95 for predicting significant LVD (EF <45%). A 
risk-score above 2.83 gave a sensitivity of 92% and specificity of 89% for predicting LVD, 
requiring only 14% of the population to undergo echocardiographic screening with a one- 
in-four pick up rate. 
Conclusion: Thus left ventdcular dysfunction is a common problem in multi-ethnic om- 
munities, has no racial difference in prevalence, is asymptomatic in half of cases, and 
has identifiable clinical and biochemical risk factors. Six simple clinical and biochemical 
markers can be used to successfully predict the presence or absence of LVD, potentially 
allowing a cost-effective targeted community-based echocardiographic screening pro- 
gramme for LVD. 
1157-154 Is Iso lated Diasto l ic  Heart  Fa i lure Tru ly  Stand Alone? 
Cheuk-Man Yu, Hong Lin, Hua Yang, Shun-Ling Kong, Steven Wai-Luen Lee, Chu-Pak 
Lau, The University of Hong Kong, Hong Kong, Hong Kong. 
Background: Definition of diastolic heart failure (DHF) relies on the use of sensitive tools 
to exclude the presence of systolic dysfunction. The use of ejection fraction of 50% as 
the cut-off point may not be adequate to address such task. We testify the hypothesis 
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that systolic dysfunction is common in DHF. Methods: Echocardiography with tissue Dop- 
pler imaging was performed in 339 subjects, in whom 92 had systolic heart failure (SHF) 
(ejection fraction <50%), 73 had DHF (ejection fraction =>50% with diastolic abnormali- 
ties on Doppler echocardiography), 68 had isolated diastolic dysfunction (DD) and 106 
normal controls. Regional myocardial velocity curves were constructed offline using a 6- 
basal, 6-mid segmental model. Results: The peak regional myocardial sustained systolic 
(Sm) and eady diastolic (Era) velocities were significantly lower in patients with SHF, 
DHF and DD than controls in almost all the myocardial segments. Likewise, the mean 
Sm (SHF < DHF < DD < Controls: 3.3 ± 1.0 < 4.6 ± 1.3 < 5.4 ± 1.0 < 6.3 ± 1.0 cm/s; all p 
<= 0.00t) and mean Em (SHF = DHF < DD < Controls; 3.6 ± 1.2 = 3.9 ± 1.3 < 5.3 ± 1.6 < 
7.2 ± 1.7 cm/s; all p < 0.001) from the six basal segments were decreased in all the dis- 
ease groups. A mean Sm of 4.4 em/s (-2 standard deviation of controls) predicted the 
presence of systolic dysfunction in 92% of patients with SHF, 52% with DHF and 14% 
with DD. Conclusions: Using tissue Doppler imaging, systolic abnormalities were evident 
in patients previously labeled as DHF, and to a much lesser extent, isolated DD. This 
indicates the common coexistence of systolic and diastolic dysfunction in a spectrum of 
different severity in the pathophysiologic process of heart failure. 
1157-155 Prevalence,  Cl in ical  Character is t ics ,  Qua l i ty  of  Life, and 
Prognosis of Patients With Congestive Heart Failure 
and Isolated Diastolic Dysfunction 
Luioi P. Badano. Maria C. AIbanese, Dario Gregori, Paola De Biaggio, Patrizia 
Rozbowsky, Daniela Miani, Claudio Fresco, Paolo M. Fioretti, Cardiovascular Science 
Department, Udine, Italy, IRCAB FOUNDATION, Udine, Italy, 
Background. Prevalence of isolated LV diastolic dysfunction (IDD) has been reported to 
be as high as 1/3 of all chronic congestive heart failure (CHF) cases, with an increasing 
prevalence in the elderly population. However, there is a paucity of prospective data 
about the prevalence and prognosis of IDD in an unselected population of pts admitted to 
hospital with CHF. 
Methods. We prospectively evaluated 179 consecutive Lots admitted in medical depart- 
ments of our hospital for CHF. Among them, 135 (59% males, median age 74 years) 
showed sinus rhythm, and no significant valvulopathy (except heart valve prosthesis or 
secondary mitral regurgitation). CHF was diagnosed using a modification of the Framing- 
ham criteria, and IDD according to the European Study Group on Diastolic Heart Failure 
echo criteria (Eur Heart J 1998;19: 990). Six-month survival of CHF pts was compared 
with that of age- and sex-matched general population living in Udine in 1995. 
Results. Twenty-nine pts (22%) had tDD; 102 (76%) LV systolic dysfunction (i.e. LV ejec- 
tion fraction <45%. There was no difference in age, gender and NYHA functional class 
between pts with IDD or LV systolic dysfunction. Six-month rehospitalisation rate (50% 
and 48%) and median in-hospital length-of-stay during readmissions (10 and 10 days) 
was similar between the 2 groups. Using the Minnesota Living with Head Failure score, 
quality of life was similar between the 2 CHF pt groups both at discharge (39.4 and 34), 
and at 6-month visit (10.4 and 10.4). Six-month survival, adjusted for age and gender, 
was similar between pts with IDD or LV systolic dysfunction (90% and 89.8%, Hazard 
Ratio= 0.99; 95%CI 0.27-3.61), and significantly reduced (Log Rank= 8.58; p<0.001) in 
comparison to that of the general population (Figure). Two pts (7% of pts with LV ejection 
fraction< 45%) did not show any echo evidence of cardiac dysfunction. 
Conclusions: our data show that, using standardized echo diagnostic criteria, prevalence 
of IDD in pts admitted to hospital with CHF seems to be lower than previously reperted. 
CHF pts with IDD showed clinical symptoms, self-perceived quality of life, re-hospitaliza- 
tion rate, and 6-month mortality similar to pts with prevalent systolic dysfunction. 
1157-156 What Is Late Morta l i ty  Af ter  Hospitalization for Heart 
Failure in the Real World? A One-Year Report From the 
Lady Davis Carmel Medical Center Registry 
Rite Yuval, Ita Levin, David A. Halon, Basil S. Lewis, Lady Davis Carmel Medical Center, 
Haifa, Israel School of Medicine, Technion-IIT, Haifa, Israel. 
Background: Heart failure (CHF) is common cause of morbidity and mortality but cur- 
rent prevalence and long-term outcome are largely unknown in general population as 
opposed to pts setocted for clinical trials. 
Patients and Methods: 362 consecutive pts discharged from hospital with clinical CHF 
or suspected CHF (drug treatment compatible with CHF/LV dysfunction) were enrolled in 
CHF registry by prospective screening of internal medical, cardiac, intensive care and 
cardiac surgical departments in 2 hospitals (1 tertiary center with cardiac surgery, 1 refer- 
ral hospital) over 6 week period in each. Survival status at 1 yr was ascertained by tele- 
phone and from governmental records. 
Results: A quarter (90/362, 25%) of CHF pts died within 12 mths, a death rate higher 
than that reported in most recent clinical CHF trials. Pts who died were older (77±10 vs 
75±11 yrs, p=0.03), but death was not predicted by new acute myocardial infarction (AMI) 
or new atrial fibrillation (AF)/paroxysmal AF at time of entry to registry or by presence of 
diabetes mellitus (31/90, 34% vs 74/272, 27%, NS), nor following correction for age and 
sex in stepwise multivariate model. 
Conclusions: In pts hospitalized for CHF or suspected CHF in the real world: 1. Late (12 
mth) mortality was higher than expected. 2. Mortality was higher in older pts. 3. Death 
was not predicted by acute event at entry to database and was marginally but not signifi- 
cantly higher in diabetics. 
Predictors of 1 year mortality 
Vital status (12 Age (yrs) AMIonindex New AF/PAF on IDDM NIDDM 
mths) admission index admission 
Dead (N=90) 77+10 6 (7%) 7 (8%) 7 (8%) 24 (27%) 
Alive (N=272) 75+11 21 (8%) 24 (9%) 21 (6%) 53 (20%) 
p value 0,03 NS NS NS NS 
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1157-157 Impaired Left Ventricular Filltng Predicts Augmented 
Ventilatory Response to Exercise in Patients With 
Chronic Heart Failure 
Faisal AI-Nasser. II1. Mohammed Yousufuddin, Costantinos Dares, Michael Henein, 
Sefan Anker, Massimo Pieopoli, Piotr Ponikowski, heart and lung institute, London, 
United Kingdom. 
Introduction. Augmented ventilator'/response to exercise ( VFJVCO 2 slope) well pre- 
dicts poor prognosis in chronic heart failure (CHF). However, the mechanisms responsi- 
ble for exercise hyperpnea in CHF have not been fully elucidated. The aim of this study 
was to determine the interrelationship between resting ECHO 2D-derived parameters 
and elevated VENCO 2 slope in CHF. Methods and results. In 38 stable CHF patients 
(33 men, 63±8 years, NYHA class fi/lll 26/12) prospective ECHO-2D examination (mean 
end diastolic diameter [EDD]: 68±8 mm, shortening fraction [SF]: 16±7%) followed by 
cardiopulmonary exercise testing (peak oxygen consumption: [peakVO2]: 19.0±6.3 ml/ 
min/kg, VENCO 2 slope 37.6±12.7). VENCO 2 slope correlated with the following 
echocardiographic parameters: short isovolumic relaxation time (IVRT, r=-0.47, 
p=0.005), decreased mitral A wave peak velocity (Ave I, r=-0.44, p=0.006), depressed 
right ventricle long axis function (RV excursion, r=-0.37, p=0.03), and left ventdcular 
restrictive filling pattern (defined as mitral E/A ratio > 1 and deceleration time ~120ms, 
r=0.47, p=0.004). There was no relationship between resting ECHO-2D indices and peak 
VO¢. Twenty (53%) pts with high VENCO 2 i.e. > 34.0) were identified: (table). 
EDD (mm) SF(%) Ave I (m/s) IVRT (ms) RV excursion Restrictive 
(ram) mitral flow 
(%) 
High VENCO 2 68±8 17±7 0.4±0.3** 24±59 12±4" 65* 
(n=20) 
Normal VE/VCO 2 68±8 18±7 0.8±0.3 50±25 17±4 29 
(n=18) 
Mean ± SD, *p<0.05, **p<0.01 high vs normal VE/VCO2Conclueion: In CHF impaired 
left ventricular filling pattern and depressed right ventricle long axis function may be 
important factors responsible for augmented ventilatory response to exercise. 
1157-158 Efficacy and Tolerability of Carvedllol in DiabeUc 
Patients With Chronic Heart Failure 
Yule Ten, Eugene Kotlyar, Anne M. Keegh, Christopher Hayward, Peter S. Macdonald. St 
Vincent's Hospital Sydney, Australia, Victor Chang Cardiac Research Institute, Sydney, 
Australia. 
Background: The benefits of beta blockers (BB) in patients with chronic heart failure 
(CHF) are well established, however, there is limited data on the impact of BB in diabetic 
CH F patients, a subgroup in whom BB have been considered relatively ocntra-indicatad. 
The aim of this study was to compare the efficacy and tolerability of the BB, carvedilol in 
diabetic and non-diabetic CHF patients. 
Methods: A retrospective analysis was conducted on 505 consecutive patients with CHF 
(434 men, 71 women) aged 55+13 years who were commenced on carvedilol between 
February 1996 and May 2001. Ninety-three patients (18%) had a history of diabetes mel- 
litus (DM group). Patients were reviewed at 3, 6, 12, 18 and 24 months then annually. 
Vital signs, NYHA functional class, 6 minute walk distance (6MWD), carvedilol dose and 
echocardiographic measurements of LV dimensions (LVEDD and LVESD) and fractional 
shortening (FS) were recorded at each visit. In addition, survival and non-fatal adverse 
events were recorded. 
Results: There were no significant differences between the DM and non-DM groups at 
baseline with respect to age, sex, duration of CHF, heart rate, diastolic blood pressure, 
serum Na+ and creatinine, drug therapy, NYHA class, LV dimensions and function. The 
DM group were significantly heavier, had lower 6MWD, and higher systolic blood pres- 
sure at baseline. A higher percentage of diabetics had ischemic heart disease (54% v 
37%, p=0.007). During a mean follow up of 32+18 months, 22% of the DM group died, 
12% underwent heart transplantation (HTx) and 11% withdraw from carvedilol due to 
adverse events. In comparison, 19% of the non-DM group died, 9% underwent HTx and 
18% were withdrawn from carvedilot due to adverse events (all p=ns compared with DM 
group). Mean maintenance carvedilol doses were 42+2 and 39+3 rag/day for DM and 
non-DM groups (p=ns). At 24 months, NYHA class and 6MWD improved significantly, 
LVEDD fell by 3.1±0.5 mm, LVESD by 4.9±0.6 mm and FS rose by 3±1% (all p < 0.0001 
versus baseline, n=226), with no significant differences between the DM and non-DM 
groups. 
Conclusion: The tolerability, clinical outcomes and beneficial effects of carvedilol on LV 
remodelling are similar in diabetic and non-diabetic CHF patients. 
1157-159 Is Additional Neurohormonal Antagonism Useful in 
Patients With Severe Chronic Heart Failure Already 
Receiving a Combination of Neurohormonal 
Antagonists? Results of the COPERNICUS Study 
Henrv Krum. Paul Mohacsi, Hugo A. Katus, Michal Tendera, Jean L. Rouleau, Michael B. 
Fowler, Andrew J. Coats, Ellen B. Roecker, Milton Packer, for the COPERNICUS Study 
Group., Monash Universi~ Prahran Victoria, Australia. 
Background. The results of the VaI.HeFT study suggested that broad based neurohor- 
monal blockade may have deleterious effects in patients with heart failure (HF), but this 
hypothesis has not been evaluated in other trials. 
Methods. The 2289 patients with severe HF in the COPERNICUS trial were randomized 
to placebo (PBO) or carvedilol (CRV), which were added to diuretics and an ACE inhibi- 
tor (+ digitalis) for up to 29 months. Of these patients, 445 were also on spironolactone at 
baseline and thus received 3 neurohormonal antagonists if they were randomized to 
CRV. Compared with those not on spironolactone, patients on spironolactone had a 
